Publications by authors named "A Morinobu"
[Objective] To investigate differences in autoantibodies, clinical features, and long-term outcomes between juvenile- and adult-onset systemic sclerosis (SSc). [Methods] Autoantibodies and survival rates over a maximum of 20 years were retrospectively analyzed in 504 Japanese patients with SSc (juvenile-onset SSc, n=17; adult-onset SSc, n=487) using data from Kyoto University Registry. [Results] The autoantibodies observed were anti-topoisomerase-I (71% vs.
View Article and Find Full Text PDFObjectives: To update the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis (CPG for RA).
Methods: The recommendations were developed based on the evidence published until the end of June 2022 using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). The steering committee, CPG panel, systematic review (SR) group, and SR support team were organised.
A 59-year-old female with anti-MDA5 antibody-positive dermatomyositis was treated with prednisolone, tacrolimus, cyclophosphamide, tofacitinib, and plasma exchange. Five months post-treatment, elevated β-D-glucan levels and a pulmonary shadow on CT were noted. was identified, leading to voriconazole initiation.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates how different biological and targeted synthetic anti-rheumatic drugs (b/tsDMARDs) affect kidney function in patients with rheumatoid arthritis (RA), particularly focusing on the incidence of chronic kidney disease (CKD).
- - Researchers followed 2,187 patients and evaluated the effects of tumor necrosis factor inhibitors (TNFi), cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig), interleukin-6 receptor inhibitors (IL-6Ri), and Janus kinase inhibitors (JAKi) on kidney health. They found that TNFi was linked to a lower CKD risk, while JAKi was associated with a higher risk.
- - The findings suggest that